Rab7A Is Required for Efficient Production of Infectious HIV-1 by Caillet, Marina et al.
Rab7A Is Required for Efficient Production of Infectious
HIV-1
Marina Caillet
1,2,3, Katy Janvier
1,2,3, Annegret Pelchen–Matthews
4, Delphine Delcroix-Gene ˆte
1,2,3,
Gre ´gory Camus
1,2,3, Mark Marsh
4, Clarisse Berlioz-Torrent
1,2,3¤*
1INSERM, U1016, Institut Cochin, Paris, France, 2CNRS, UMR8104, Paris, France, 3Universite ´ Paris Descartes, Sorbonne Paris Cite ´, Paris, France, 4Cell Biology Unit, MRC
Laboratory for Molecular Cell Biology, University College London, London, United Kingdom
Abstract
Retroviruses take advantage of cellular trafficking machineries to assemble and release new infectious particles. Rab
proteins regulate specific steps in intracellular membrane trafficking by recruiting tethering, docking and fusion factors, as
well as the actin- and microtubule-based motor proteins that facilitate vesicle traffic. Using virological tests and RNA
interference targeting Rab proteins, we demonstrate that the late endosome-associated Rab7A is required for HIV-1
propagation. Analysis of the late steps of the HIV infection cycle shows that Rab7A regulates Env processing, the
incorporation of mature Env glycoproteins into viral particles and HIV-1 infectivity. We also show that siRNA-mediated
Rab7A depletion induces a BST2/Tetherin phenotype on HIV-1 release. BST2/Tetherin is a restriction factor that impedes
HIV-1 release by tethering mature virus particles to the plasma membrane. Our results suggest that Rab7A contributes to
the mechanism by which Vpu counteracts the restriction factor BST2/Tetherin and rescues HIV-1 release. Altogether, our
results highlight new roles for a major regulator of the late endocytic pathway, Rab7A, in the late stages of the HIV-1
replication cycle.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) assembly,
budding and release involves a highly orchestrated series of
interactions between proteins encoded by the virus, viral genomic
RNA and key cellular components of the cellular membrane sorting
machineries [1–5]. These late steps of the viral replication cycle are
coordinated by the viral Pr55 Gag precursor protein and are
initiated by the bindingof Gag complexes to the cytosolic face of the
plasma membrane. This docking is regulated by the exposure of a
myristoyl moiety that is co-translationally coupled to the Matrix
(MA) domain of Gag, and by interaction of MA with phosphati-
dylinositol 4,5 bisphosphate [PI(4,5)P2] [6,7]. Vesicular trafficking
components, such as the clathrin adaptor protein (AP) complexes,
the Golgi-localized c-ear containing Arf-binding (GGA) and ADP
ribosylation factor (ARF) proteins have also been implicated in Gag
trafficking and virus release [8]. The AP-1 and AP-3 adaptor
complexes, which normally select the cargoes carried by clathrin-
coated vesicles, interact with Gag and appear to participate in its
trafficking and in virus release [9–11]. Similarly, ARF proteins, key
regulators of intracellular trafficking, support Gag trafficking to the
plasmamembrane whereasthe GGA proteins, monomeric clathrin-
binding factors regulating the sorting of mannose 6-phosphate
receptor (MPR) from the TGN to endosomes, negatively regulate
the production of virus particles [12]. In addition, transport
machineries, including the AP-1 and AP-2 adaptor complexes
[13–17] and TIP47 (tail-interacting protein of 47 kDa) [18–20] are
involvedintrafficking oftheHIV-1envelope glycoprotein(Env) and
its incorporation into virions.
For scission, nascent viral particles hijack the ESCRT
machinery (Endosomal Sorting Complexes Required for Trans-
port) which normally functions in cytokinesis [21,22], multi-
vesicular body (MVB) formation and the targeting of ubiquitinated
cargoes to the intralumenal vesicles of MVB [23]. Gag recruits
TSG101, a component of ESCRT-I, or the ESCRT-associated
protein AIP-1/ALIX through short peptide motifs in its C-
terminal p6 domain, and this allows the recruitment of ESCRT-III
complexes to promote the budding and scission of HIV-1 particles
[24–27].
Following Gag-ESCRT-mediated viral particle scission, the
accessory protein Vpu of HIV-1 promotes the release of mature
viral particles by counteracting the action of the newly identified
cellular restriction factor BST2/Tetherin (bone marrow stromal
cell antigen 2, also called CD317/HM1.24) that impedes the
release of fully assembled HIV-1 particles by physically tethering
them to the cell surface. Vpu counteracts this restriction by
downregulating BST2 [28,29]. Interestingly, we recently showed
that HRS (also called hepatocyte growth factor-regulated tyrosine
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is required for Vpu to efficiently modulate BST2 expression and
promote HIV-1 release, highlighting an additional role of the
ESCRT machinery in virus production [30].
Rab GTPases are key regulators of membrane-trafficking
events, including exocytosis and endocytosis, in eukaryotic cells.
To identify additional cellular components required for HIV-1
formation, we explored the role of eight ubiquitously expressed
Rab proteins (Rab1A, Rab4A, Rab5A, Rab6A, Rab7A, Rab8A,
Rab9A, Rab11A) involved in the endocytic and exocytic
pathways. Each of these proteins localizes to distinct intracellular
compartments and regulates specific steps of vesicle trafficking by
recruiting tethering, docking and fusion factors as well as actin- or
microtubule-based motor proteins [31–34]. Using specific RNA
interference targeting Rab proteins, and virological assays, we
demonstrate that Rab7A is required for efficient HIV-1 propaga-
tion. Rab7A plays an important role in the organization of late
endocytic compartments [35–42], and in the maturation of late
endosomes and phagosomes and their fusion with lysosomes [43–
46]. Recent studieshaveshownthat Rab7A inducesthe recruitment
of dynein and dynactin motors and regulates transport toward the
minus-end of microtubules [47]. Analysis of the later stages of HIV-
1 replication shows that Rab7A is required for efficient HIV-1
release and infectivity. We show that Rab7A depletion reduces Env
processing, increasing the levels of the uncleaved Env precursor
gp160 in virus-producing cells and in virus particles, thereby
impairing viral infectivity. Moreover, Rab7A knockdown causes an
accumulation of virus particles at the surface of infected cells, an
effect related to the expression of the restriction factor BST2/
Tetherin. We find that Rab7A participates in the mechanism by
which Vpu counteracts BST2/Tetherin, thereby promoting HIV-1
release.Altogether,ourresultsshow thatRab7Aisakeyregulatorin
the late stages of the HIV-1 infection cycle, influencing several steps
in the production and release of infectious viral particles.
Results
Rab7A is essential for HIV-1 propagation
To explore the role of Rab proteins in the HIV-1 replication
cycle, we analyzed the effect of Rab1A, Rab4A, Rab5A, Rab6A,
Rab7A, Rab8A, Rab9A and Rab11A depletion on HIV-1
propagation in HeLa MAGI P4-R5 cells, which stably express
the HIV-1 receptor/coreceptors CD4, CCR5 and CXCR4. These
cells have the b-galactosidase reporter gene under the control of
the HIV-1 LTR, allowing the detection of infected cells by X-gal
staining (blue cells). HeLa P4-R5 cells were treated with siRNAs
targeting the Rab proteins or control siRNA targeting the
luciferase sequence (siLuc) (Figure S1A). Treated cells were then
infected with HIV-1 NL4-3 strain (referred herein as HIV-1) at a
multiplicity of infection (MOI) of 0.005 and left for 4 days to
enable the virus to spread in the cultures. HIV-1 propagation was
monitored by X-gal staining of infected cells (Figure 1A) and by
quantification of the HIV capsid protein CAp24 released into the
medium (Figure 1B). Depletion of Rab proteins was confirmed by
western blot analysis of the cells. Silencing was efficient and
specific as extinction of each Rab tested did not affect the
expression of the others (Figure S1B). No significant alteration of
HIV-1 replication was observed following depletion of Rab1A and
Rab5A compared to the control cells treated with siRNA against
luciferase (Figures 1A and 1B). A moderate decrease in HIV-1
replication was observed upon knockdown of Rab4A, Rab8A,
Rab9A and Rab11A, with ,30 to 60% less CAp24 detected in the
supernatants of these cells compared to the control. The effects of
Rab9A and Rab11A depletion were similar to those described by
Murray and collaborators [48]. Moreover, consistent with a
previous study [49], extinction of Rab6A expression reduced
(.60% decrease) HIV-1 dissemination (Figures 1A and B).
Interestingly, the most potent effect on HIV-1 propagation was
observed in cells depleted of Rab7A. Indeed, four days post-
infection only a few infected cells were observed in Rab7A-
depleted cultures (Figure 1A) and the level of CAp24 in the cell
supernatants was 30-fold lower than the control (Figure 1B). These
results suggest a major role for Rab7A in HIV-1 propagation in
HeLa P4-R5 cells.
Rab7A is required for the release of infectious HIV-1
particles
To decipher the role of Rab7A in HIV-1 replication, we tested
whether the reduction of HIV-1 propagation observed in Rab7A-
depleted HeLa P4-R5 was a consequence of an alteration of HIV-
1 entry into cells. HeLa P4-R5 cells were treated with siRNAs
targeting Rab7A or luciferase (siLuc; negative control) and
infected for 2 hours with HIV-1 at MOI=0.005. The CXCR4
antagonist AMD3100 was added to the culture medium 2 hours
post-infection to block re-infection of the cells. Entry of HIV-1 was
quantified by counting the number of infected cells. A modest
decrease of HIV-1 entry (,35%) was observed in Rab7A-depleted
cells compared to the control cells (Figure S2A). Similar results
were obtained for HIV pseudotyped with VSV-G envelope (the
virus used in the subsequent experiments; ,30% decrease; Figure
S2B), indicating that HIV-1 entry was not dramatically affected by
Rab7A depletion. These data therefore cannot fully explain the
dramatic reduction of HIV propagation observed in Rab7A-
depleted cells (Figure 1).
We next investigated whether Rab7A is involved in the late
stages of HIV-1 replication, corresponding to the budding and
release of infectious particles. HeLa cells were transfected with
siRNA against Rab7A or control siRNA, and infected with HIV-1
NL4-3 pseudotyped with VSV-G envelope at a MOI of 0.5. VSV-
G pseudotyping enabled us to monitor HIV-1 production after a
single round of infection in HeLa cells. Twenty-four hours after
infection, the impact of Rab7A depletion on the production of
infectious HIV-1 was assessed. To better validate our siRNA
experiments, two distinct siRNAs against Rab7A (referred to as
siRab7A and siRab7A-2) were used. Rab7A expression was
checked by western blotting (Figure 2A). The expression level and
Author Summary
Human immunodeficiency virus (HIV) propagation requires
the assistance of host cell factors at all stages of the
infection cycle. HIV exploits components of the cellular
membrane sorting machinery for its assembly, budding
and release. Rab GTPases are key regulators of membrane-
trafficking events, including exocytosis and endocytosis, in
eukaryotic cells. Here we show that the late endosome
associated Rab7A plays a major role in HIV-1 replication.
We find that Rab7A regulates the production of infectious
HIV-1 particles at two critical stages. First, Rab7A is
required for efficient Env processing and, thus, for the
incorporation of mature HIV-1 envelope glycoproteins into
virions. Second, Rab7A contributes to the mechanism that
counteracts the restriction imposed on HIV-1 release by
the cellular restriction factor BST2/Tetherin that physically
tethers viral particles to the plasma membrane of infected
cells. Altogether these data highlight new roles for a major
player of the late endocytic pathway, Rab7A, in the late
stages of the HIV-1 replication cycle.
Rab7A and Production of Infectious HIV Particles
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blotting, and virus release was monitored by ELISA quantification
of the processed Gag product CAp24. Western blot analysis
revealed no major alteration of Gag processing upon Rab7A
depletion but showed a strong accumulation of Gag precursor and
processed products (Gag p41, CAp24, MAp17) in Rab7A
knockdown cells compared to the control (Figure 2A, compare
lanes 2–3 to lane 1). Consistent with this observation, ELISA
quantification of CAp24 showed a 2 to 6-fold increase in cell-
associated CAp24 depending on the siRNA used (Figure 2B). The
accumulation of cell-associated Gag, together with a ,70%
decrease of CAp24 released into the supernatant of Rab7A-
depleted cells (Figure 2B), suggested that Rab7A is essential for
efficient release of HIV-1 from HeLa cells.
We also scored the infectious titres of the particles by infection
of HeLa TZM-bl indicator cells. The results were normalized to the
amount of CAp24 present in the cell supernatants (referred herein as
HIV-1 infectivity).Interestingly, viral particles produced from Rab7A
knockdown cells were poorly infectious (70 to 80% less infectious
compared to the control), showing that silencing of Rab7A not only
reduces the release of viral particles, but also diminishes the infectivity
of the HIV-1 particles that are released (Figure 2C).
Rab7A is essential for HIV-1 infectivity
We investigated whether the reduced infectivity of virus
particles produced from Rab7A-depleted cells might be due to
an alteration of viral genomic RNA packaging into the budding
virions, as it has been shown that HIV RNAs are transported on
endosomal vesicles [50,51]. The amount of viral genomic RNA
(gRNA) present in the viral preparations from siRNA treated
HeLa cells was measured by real time PCR (Figure S3D) and
normalized to the amount of CAp24 released (Figure S3A). No
Figure 1. Rab7A depletion reduces HIV-1 propagation. HeLa P4-R5 MAGI cells transfected with either siRNA control Luciferase (siLuc) or
siRNAs targeting Rab proteins (siRab) were not infected (NI) or infected with wild type HIV-1 NL4-3 (HIV-1) at a low MOI (0.005), and left for 4 days to
allow viral propagation. (A) X-Gal staining of infected cell cultures. The blue staining corresponds to infected cells after multiple rounds of HIV-1
infection. This experiment is representative of 3 independent experiments performed in duplicate. (B) HIV-1 propagation was scored by measuring
the amount of HIV-1 CAp24 released into the culture supernatants by ELISA quantification. The amounts of released CAp24 were normalized to those
obtained for the control cells, set as 100%. Bars represent the means of percentage values 6 SD for 3 independent experiments. P values were
calculated based on t-test. Significant results (***, p,0.001, **, p,0.01 and *, p,0.05) are indicated (n.s. = not significant).
doi:10.1371/journal.ppat.1002347.g001
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Rab7A depletion does not perturb gRNA packaging into viral
particles. Interestingly, higher levels of viral genomic RNA were
detected in Rab7A-depleted producer cells compared to controls
(Figure S3E). Along with the increase of cell-associated CAp24
(Figure S3B), these data suggest that Rab7A silencing induces the
accumulation of assembled virus in the cells.
To further characterize the impact of Rab7A depletion on HIV-1
infectivity,weanalyzed thecomposition ofviralparticlesproducedby
Rab7A-depleted HeLa cells by western blotting for Gag and Env.
Western blot analysis of equal volumes of the viral preparation
produced from siRNA-treated cells showed a decrease in the amount
of Gag CAp24 and the Env proteins, TMgp41 and SUgp120, upon
Rab7A depletion compared to the control (Figure 3B),consistent with
the decrease in viral particle release shown in Figure 2.
Surprisingly, similar levels of immature Env precursor (gp160)
were detected in both viral samples, suggesting that Rab7A
knockdown may affect Env processing in the infected cells
(Figure 3B). To investigate this, equivalent amounts of virus
particles were loaded (30 mg) and the Env content was analyzed by
western blotting (Figure 3C). Here, compared to the control, little
processed SUgp120 and TMgp41 was detected in the virus
particles produced by the Rab7A-depleted cells. By contrast,
higher levels of gp160 were seen in these viruses. Increased
amounts of gp160 and the mature products, SUgp120 and
TMgp41, were also detected in the corresponding cell lysates,
suggesting that the reduced levels of mature Env observed in the
virions were not due to the absence of these Env subunits in the
producer cells (Figure 3A). We further investigated Env processing
in infected cell lysates. Control cell lysates (160 mg) or lysates from
Rab7A-depleted cells (80 mg was loaded to avoid saturating the
Env signal in Rab7A knockdown samples) were analyzed and the
intensities of the gp160 and SUgp120 bands were quantified. Env
processing efficiency was determined by calculating the ratio
between the signal of SUgp120 to those of SUgp120 + Env gp160
(Figures 3D and 3E). This revealed a lower efficiency of Env
processing in Rab7A knockdown cells (Figure 3E), which explains
the presence of mainly immature Env gp160 in the virus particles
and thus the decreased infectivity of the virus released from
Rab7A knockdown cells (Figure 2C and S3C).
Together, these data show that Rab7A silencing leads to a
reduction in production of HIV-1 particles. As these particles
contain the Env precursor gp160 and reduced levels of mature
Env, their infectivity is reduced. Thus, Rab7A is required for the
efficient production of infectious HIV-1.
Rab7A depletion induces the accumulation of mature
viruses at the cell surface
Since the previous experiments indicated that Rab7A depletion
may inhibit HIV-1 release from infected cells, siRNA-treated HeLa
cells infected with VSV-G pseudotyped NL4-3 HIV-1 were analyzed
by immunofluorescence (Figure 4A and 4B). Labelling with
antibodies directed against the Env SUgp120 subunit and CAp24
(detecting the CA sub-product and the Gag precursor) showed
numerous infected cells with small spots that co-stained for Gag and
Env. Staining of Rab7A knockdown cells showed an increased
number of larger, more prominent spots co-labelled with anti-Env
and anti-CA antibodies at the periphery of the cells compared to the
control (see white arrows on Figure 4A, compare panels c and g).
Moreover, the intracellular staining of Env and Gag also appeared
more intense in Rab7A-depleted cells (Figure 4A, panels e-h), which
correlates with the increased amount of cell-associated Gag and Env
detected by western blotting (see Figures 2A and 3A).
In order to determine whether the viral products accumulated
at the periphery of the cells were present at the cell surface and
corresponded to mature viruses, non-permeabilized cells were
stained for cell surface Env, then fixed, permeabilized and stained
Figure 2. Rab7A depletion reduces the release of HIV-1 particles. HeLa cells transfected with either siRNA control Luciferase (siLuc) or siRNA
targeting Rab7A proteins (siRab7A and siRab7A-2) were infected with the VSV-G-pseudotyped HIV-1. (A) Western blot analysis of infected siRNA-
treated cells. Tubulin is the loading control. This western blot is representative of 3 independent experiments. (B) The amounts of cell associated
(Cell-associated CAp24, black graph bars) and released HIV-1 CAp24 (Released CAp24, grey graph bars), measured by ELISA for cell cultures depleted
for Rab7A or Rab7A-2 were normalized to those obtained for the control cells, set as 100%. Bars represent the mean of percentage values 6 SD for 3
independent experiments. (C) Infectivity of HIV-1 released from the cells. Virus titres were normalized for the quantity of released CAp24 (Infectious
units/mg CAp24) and compared to the infectivity of virus from control cells, set as 100%. Bars represent the means of percentage values 6 SD for 3
independent experiments. (B-C) P values were calculated based on t-test. Significant results (***, p,0.001, **, p,0.01 and *, p,0.05) are indicated.
doi:10.1371/journal.ppat.1002347.g002
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MAp17 and thus mature viruses. As shown on Figure 4B, Env
labelling present at the cell surface was increased upon Rab7A
knockdown (compare panels a and e) and mostly co-localized with
MAp17 labelling present in large spots located at cell peripheries
(panel f). The increased number of spots co-labelled with MA and
Env at the cell surface of Rab7A-depleted cells (see white arrows)
suggests that Rab7A silencing may induce the accumulation of
mature viruses at the cell surface.
To investigate directly whether depletion of Rab7A leads to the
accumulation of virus particles at the cell surface, ultrathin
cryosections from infected cells were immunolabelled for CAp24 or
MAp17 and Env and examined by electron microscopy (Figure 4C).
Large clusters of Env-containing virus particles were observed at the
surface of Rab7A-depleted cells (Figure 4C, panels a, d and e), while
on control cells we usually only saw single virus particles or small
groups of labelled virions (Figure 4C, panels b and c). Most virus
particles had a mature morphology and stained strongly with the
antibody 4C9, which detects only the cleaved mature MAp17 and
therefore labels primarily mature virus particles, though some
immature virus particles and budding figures were also observed
(black arrows in Figure 4C, panels c and d, see also Figure S4).
Together, these data show that Rab7A silencing induces the
accumulation of virus clusters at the surface of HIV-1 infected cells.
Reduced HIV-1 release in Rab7A-depleted cells is related
to expression of the restriction factor BST2/Tetherin
The accumulation of mature viral particles at the surface of
infected cells, and decreased release of viral particles, are
reminiscent of the phenotype described in BST2-expressing cells
Figure 3. Rab7A depletion affects Env processing and the incorporation of mature Env into viral particles. HeLa cells transfected with
either siRNA control Luciferase (siLuc) or siRNA targeting Rab7A (siRab7A) were infected with VSV-G pseudotyped wt NL4-3 HIV-1 (HIV-1 WT). This
experiment is representative of 3 independent experiments done in duplicate. (A) Equal amounts of cell lysate (50 mg protein) were loaded to
visualize the intracellular accumulation of viral proteins in Rab7A-depleted cells. (B) Equal volumes of the virus samples were loaded to visualize the
decrease of virus released from Rab7A-depleted cells. (C) Equal amounts of CAp24 (30 mg) per lane were loaded to visualize Env content for a fixed
amount of viral particles. (D) Further analysis of cell lysates. For three independent experiments (Exp. 1, 2, and 3), 160 mg protein of control cell
lysates or 80 mg protein of Rab7A-depleted cell lysates were loaded and Env products (Env gp160 precursor, SUgp120 and TMgp41) were detected
using anti-SUgp120 (110H) and anti-TMgp41 (41A) antibodies. (E) Env signals were quantified for these 3 independent experiments and values
obtained were used to calculate the Env processing efficiency (the ratio between the signals detected for the processed SUgp120 subunits relative to
the total Env detected, gp160 + SUgp120. Bars represent the mean of the ratios 6 SD for these 3 experiments. P values were calculated based on t-
test. Significant results (**, p,0.01) are indicated.
doi:10.1371/journal.ppat.1002347.g003
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to physically tether newly formed virus particles at the surface of
infected cells, preventing their release. Vpu relieves this restriction
by promoting the degradation of BST2 and downregulating its cell
surface expression [28–30,52–56].
To investigate whether the effect of Rab7A depletion on HIV-1
release is related to Vpu-induced BST2 downregulation, we
compared the effect of Rab7A depletion on HIV-1 production in
restrictive HeLa cells and in HEK 293T, which do not normally
express BST2 and are referred to as ‘‘non-restrictive’’ cells [28,29].
RNAi-mediated Rab7A knockdown was similar in HEK 293T
and HeLa cells (. 95%; Figure 5A). In HeLa cells (Figures 5A and
5B), Rab7A depletion inhibited the release of HIV-1 and induced
an accumulation of cell-associated CAp24 as shown before. In
HEK 293T cells, a reduced amount of CAp24 was detected in the
supernatant. However, this was paralleled by a decrease in the
amount of cell-associated CAp24 in Rab7A knockdown HEK
293T cells (Figures 5A and 5B), suggesting that the decreased
CAp24 release observed in HEK 293T cultures most likely reflects
lower levels of cell-associated CAp24 rather than a defect in virus
release (Figure 5B).
We also analyzed the outcome of Rab7A silencing on the
production of wt and Vpu-defective HIV-1 from HeLa cells with or
without BST2. HeLa cells were transfected with control siRNA or
siRNAs targeting Rab7A and BST2 alone or together and
subsequently infected with either VSV-G pseudotyped wt NL4-3
HIV-1 (HIV-1 WT) or VSV-G pseudotyped Vpu-defective NL4-3
HIV-1 (HIV Udel) at an equivalent MOI (MOI=0.5). As
previously reported [28,29,57] in HeLa cells, HIV-1 release is less
efficient in the absence of Vpu; less CAp24 was released into the
supernatant of HIV-1 Udel-infected cells (Figures 5C and 5D,
compare lanes 1 and 5). Interestingly, Rab7A depletion reduced
release of both WT and Udel viruses and increased the level of cell-
associated Gagproducts(Figures5Cand 5D,comparelanes1and2
with lanes 5 and 6). As previously described [28,29], the release of
Vpu-defective HIV-1 was restored in cells depleted for BST2, as
higher amounts of Udel virus were produced from these cells
compared to control cells (Figures 5C and 5D, compare lanes 5 and
7). Interestingly, wt and Udel HIV-1 release was less affected by
Rab7A depletion in HeLa cells devoid of BST2 (Figure 5C,
compare CAp24 released, lanes 2 and 4, and lanes 6 and 8),
indicating that the impact of Rab7A on HIV-1 release may be
related to BST2. However, we noted that the level of cell-associated
Gag in Rab7A and BST2-depleted cells, although lower than in
Rab7A knockdown cells, remains higher than the level detected in
cells depleted for BST2 alone. Thus, the striking increase in cell-
associated Gag observed in Rab7A-depleted cells may result not
only from BST2-induced retention of viral particles, but also from
additional functions of Rab7A on virus release. Nevertheless, our
results indicate that, at least in part, the effect of Rab7A knockdown
onHIV-1releaseisrelatedtoBST2expressioninthe producercells.
To further characterize the impact of Rab7A depletion on Vpu-
induced downregulation of BST2, we analyzed the steady state
level of BST2 (Figure 5C) in siRNA treated-infected cells by
western blotting. As previously described [30,52,53,56], HIV-1
Vpu reduced BST2 levels in infected cells (Figure 5C, compare
lanes 1 and 5). Interestingly, downregulation of BST2 expression
by Vpu was abrogated by Rab7A depletion.
Rab7A regulates the constitutive turnover of BST2
We have previously shown that BST2 undergoes constitutive
ESCRT-dependent sorting for lysosomal degradation and that this
degradation is enhanced by Vpu expression [30]. As Rab7A is a
key regulator of late endocytic compartments and is involved in
targeting cargoes to the lysosomal degradation pathway [35–41],
we tested whether Rab7A regulates the degradation of BST2.
Uninfected HeLa cells were transfected with siRNA targeting
Rab7A or a control siRNA, and the turnover of BST2 was
monitored after treating the cells with cycloheximide. We observed
that almost 80% of BST2 was degraded over 4 h in cells
transfected with control siRNA (Figure 6A, siLuc). By contrast, the
half-life of BST2 was increased in Rab7A-depleted cells (Figure 6A,
siRab7A), with less than 5% of BST2 degraded after 4 h
cycloheximide treatment. As an internal control, we monitored
the turnover of EGF receptors (EGF-R) following EGF stimula-
tion. Upon ligand binding, EGF-R is targeted to MVBs prior to
lysosomal degradation [41,58–60]. Consistent with previous
studies [60], knockdown of Rab7A inhibited EGF-induced EGF-
R degradation compared to control cells (Figure 6A).
We also explored the intracellular location of BST2 in the
absence of Rab7A expression. Immunofluorescence analysis
revealed an accumulation of BST2 in enlarged CD63+ late
endocytic compartments compared to the control cells, consistent
with a stabilization of the protein (Figure 6B). Quantification of the
colocalization between BST2 and CD63 using Pearson’s correla-
tion coefficient [61] validated that BST2 is retained in CD63
positive compartments after treatment with Rab7A siRNA (0.36
for control siRNA treated cells vs 0.54 for Rab7A siRNA treated
cells; Figure 6C). Immunolabelling of ultrathin cryosections
demonstrated that BST2 was present in MVB (Figure 6D) which
co-stained for CD63 (Figure 6D, panel c).
To confirm these data, we analyzed the effect of overexpressing
an inactive form of Rab7A, Rab7A T22N, on BST2 turnover and
localization. HeLa cells were transfected with GFP-Rab7A WT or
T22N. The turnover of BST2 was monitored after incubating the
cells in growth medium containing cycloheximide. We noted that
lower levels of BST2 were detected in cells transfected with GFP-
Rab7A WT after 4 h cycloheximide treatment whereas BST2 was
stabilized in GFP-Rab7A T22N expressing cells (Figure S5A,
GFP-Rab7A T22N). Moreover, analysis of the distribution of
BST2 in GFP-Rab7A T22N expressing cells showed a redistribu-
tion and accumulation of BST2 in intracellular compartments
(Figure S5B). Together, these data indicate that the inactive form
of Rab7A blocked the degradation of BST2, and show that Rab7A
is involved in the constitutive turnover of BST2.
Rab7A depletion perturbs Vpu-induced BST2
degradation
It has been reported that Vpu increases the rate of BST2
degradation [30]. We thus investigated whether Rab7A partici-
pates in Vpu-induced BST2 turnover. Cycloheximide chase
Figure 4. Silencing of Rab7A induces accumulation of virus clusters at the cell surface. HeLa cells transfected with either siRNA control
Luciferase (siLuc) or siRNA targeting Rab7A (siRab7A) were infected with VSV-G-pseudotyped HIV-1 and analyzed 24 h after infection. (A) Cells were
fixed with PFA and immunolabelled with anti-CAp24 (CAp24) and anti-Env (Env SUgp120) antibodies. (B) Living cells were stained at 4uC with anti-
Env antibody (Env SUgp120) and appropriate fluorophore-conjugated secondary antibody. Cells were then fixed with PFA, permeabilized and
labelled with anti-MAp17 (MAp17) antibody. White arrows show spots co-labelling for Env and CAp24 or MAp17 at the cell surface. Scale
bars=20 mm. (C) Cells were fixed and processed for EM immunolabelling. Ultrathin cryosections were double labelled for Env with 10 nm protein A-
gold particles and for either CAp24 (panels a, b, c) or MAp17 (panels d and e) and 5 nm protein A-gold. Virus particles were detected at the cell
surface. Black arrows mark immature viruses and buds. Scale bars=200 nm.
doi:10.1371/journal.ppat.1002347.g004
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PLoS Pathogens | www.plospathogens.org 7 November 2011 | Volume 7 | Issue 11 | e1002347Figure 5. Reduced HIV-1 release after depletion of Rab7A is related to expression of the restriction factor BST2. (A–B) Effect of Rab7A
depletion on the release of HIV-1 particles from non-restrictive HEK 293T cells. HeLa cells and HEK 293T cells transfected with either control siRNA
(siLuc) or siRNA targeting Rab7A were infected with VSV-G-pseudotyped HIV-1. (A) Western blot analysis of infected siRNA-treated cells (Upper
panels) and viral particles released into the supernatant (Lower panel). Tubulin is the loading control. This western blot is representative of 3
independent experiments done in duplicate. (B) CAp24 levels present within the cells (Cell-associated CAp24, dark grey graph bars) and released
from the infected cells (Released CAp24, light-grey graph bars), measured by ELISA quantification for Rab7A-depleted cells, were normalized to those
obtained for the control cells, set as 100%. Bars represent the mean of percentage values 6 SD from 3 independent experiments. P values were
calculated based on t-test. Significant results (***, p,0.001 and **, p,0.01) are indicated. (C-D) Effect of Rab7A and BST2 depletion on the release of
HIV-1 particles from restrictive HeLa cells. HeLa cells were transfected with either control siRNA Luciferase (siLuc) (lanes 1 and 5) or siRNA targeting
Rab7A protein (siRab7A) (lanes 2 and 6), BST2 (siBST2) (lanes 3 and 7) or both Rab7A and BST2 (lanes 4 and 8). Cells were then infected with either
VSV-G pseudotyped wt NL4-3 HIV-1 (HIV-1 WT) viruses or VSV-G pseudotyped Vpu-defective NL4-3 (HIV-1 Udel) viruses. (C) Western blot analysis of
infected siRNA-treated cells. Tubulin is the control loading. Equal volumes of the viral samples were loaded to visualize the partial rescue of virus
release in Rab7A/BST2-depleted cells. The western blot is representative of 3 independent experiments done in duplicate. (D) HIV-1 CAp24 present
within the cells (Cell-associated CAp24, black graph bars) and CAp24 released into the supernatant of the infected cells (Released CAp24, grey graphs
bars), measured by ELISA quantification for Rab7A and/or BST2-depleted cells infected with wt or Udel HIV-1, were normalized to those of the control
cells infected with wt HIV-1, set to 100%. Bars represent the means of percentage values 6 SD for 3 independent experiments. P values were
calculated based on t-test. Significant results (***, p,0.001, **, p,0.01 and *, p,0.05) are indicated (n.s. = not significant).
doi:10.1371/journal.ppat.1002347.g005
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with control (siLuc) or Rab7A siRNA and infected with WT (HIV-
1 WT) or Vpu-deleted (HIV-1 Udel) NL4-3 HIV pseudotyped
with VSV-G (MOI =0.5) (Figure 7A). As previously shown,
expression of Vpu enhanced BST2 degradation in infected cells.
Low levels of BST2 were detected in control cells infected with
Figure 6. Rab7A sorts BST2 for degradation. (A) Analysis of BST2 turnover upon Rab7A depletion. HeLa cells transfected with either siRNA
control Luciferase (siLuc) or siRNA targeting Rab7A were incubated with cycloheximide (10 mg/ml) and, where indicated, with EGF for the times
indicated above each lane. Cells were lysed and equivalent amounts of each sample (50 mg of protein) were analyzed using western blotting with
antibodies against BST2, Rab7A, EGF-Receptor (EGF-R) and tubulin as a loading control. For each sample, the intensity of the BST2 signal was
quantified using ImageJ software and used to calculate the amount of BST2 remaining at each time point, relative to t=0, set to 100% in the graph
shown on the right. (B) Effect of Rab7A silencing on BST2 distribution. HeLa cells transfected with either siRNA control Luciferase (siLuc) or siRNA
targeting Rab7A were permeabilized before fixation and staining with mouse polyclonal anti-BST2 and appropriate secondary fluorophore-
conjugated antibodies. Cells were then labelled with mouse CD63-FITC. Scale bars=20 mm. (C) CD63-BST2 colocalization was assessed by calculating
the Pearson correlation coefficient on twenty images per condition using the JACoP plugin on ImageJ. (D) BST2 accumulates in MVB in Rab7A
knockdown cells. Ultrathin cryosections of HeLa cells transfected with siRNA targeting Rab7A and infected with VSV-G-pseudotyped HIV-1 were
stained with mouse (panels a, b) or rabbit (panel c) polyclonal anti-BST2 antibodies and 10 nm PAG. In panel c, sections were co-stained for CD63 with
5 nm PAG. Arrows mark some of the 10 nm PAG particles. N, nucleus. Scale bars=200 nm.
doi:10.1371/journal.ppat.1002347.g006
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HIV-1 (HIV-1 Udel) (Figure 7A, compare lanes 1–2 with lanes
5–6). Interestingly, Rab7A knockdown stabilized BST2 over
4 hours in cells infected with HIV-1 WT (lanes 3–4) to a level
similar to that observed in cells infected with HIV-1 Udel (lanes 5–
6), indicating that Vpu accelerates the intracellular degradation of
BST2 by a mechanism involving Rab7A. Finally, we explored the
localization of BST2 in infected cells after knockdown of Rab7A.
As shown in non-infected cells (Figure 6B), upon Rab7A depletion,
BST2 accumulated in intracellular compartments, many of which
co-stained for CD63 (Figure 7B).
Altogether, these data support the hypothesis that the late
endocytic pathway, regulated by Rab7A, is involved in Vpu-
induced degradation of BST2.
Rab7A depletion reduces the cell surface expression of
BST2
We analyzed whether the intracellular accumulation of BST2
observed upon Rab7A depletion affected the cell surface
expression of BST2. Uninfected HeLa cells were transfected with
control siRNA or with siRNA targeting Rab7A and the cell
surface levels of BST2 were assessed by immunofluorescence
staining and flow cytometry (Figures 8A and 8B). In Rab7A-
depleted cells, a marked decrease of cell surface BST2 was
observed by immunofluorescence (Figure 8A) and flow cytometry
(Figure 8B), compared to cells transfected with control siRNA
(siLuc), while a higher expression of CD63 and EGF-R was
detected at the cell surface (data not shown). Together, our data
suggest that depletion of Rab7A slows the degradation of BST2
Figure 7. Depletion of Rab7A increases the cellular BST2 levels in the presence or absence of Vpu. (A) Analysis of BST2 turnover upon
Rab7A depletion in HIV-1 infected cells. HeLa cells transfected with either control siRNA (siLuc) or siRNA targeting Rab7A were infected with either
VSV-G pseudotyped wt NL4-3 (HIV-1 WT) or VSV-G pseudotyped Vpu-defective NL4-3 (HIV-1 Udel) HIV-1 at a MOI of 1. Forty-eight hours after
infection, some of the cells were incubated with cycloheximide for 4 h and lysed. Cell lysates were analyzed by western blot. Tubulin is the loading
control. These data are representative of 2 independent experiments. (B) Effect of Rab7A silencing on BST2 distribution in HIV-1 infected cells. HeLa
cells transfected with either control siRNA (siLuc) or siRNA targeting Rab7A were infected with VSV-G pseudotyped NL4-3 HIV-1 WT and processed for
immunolabelling with mouse polyclonal BST2, human HIV-1 Env (2G12) and mouse CD63-FITC antibodies. Cells were imaged by confocal microscopy.
Env staining discriminates between infected cells (stars) and non-infected cells. Scale Bars=20 mm.
doi:10.1371/journal.ppat.1002347.g007
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PLoS Pathogens | www.plospathogens.org 10 November 2011 | Volume 7 | Issue 11 | e1002347Figure 8. Rab7A decreases BST2 cell surface expression and is required for Vpu-induced BST2 cell surface downregulation. (A–B)
Rab7A decreases BST2 cell surface expression. HeLa cells were transfected with either siRNA control Luciferase (siLuc) or siRNA targeting Rab7A
(siRab7A). (A) Forty-eight hours after transfection, cells were stained at 4uC with anti-BST2 antibody and appropriate fluorophore-conjugated
secondary antibody. Cells were then fixed with PFA. Scale bars=20 mm. (B) Forty-eight hours after transfection, cells were stained with a mouse
monoclonal antibody against BST2 or isotype control mouse IgG1. Cells were then stained with Alexa 647-conjugated donkey anti-mouse antibody,
fixed and processed for flow cytometry analysis. These data are representative of 3 independent experiments. (C–D) Rab7A is required for Vpu-
induced cell surface downregulation of BST2. HeLa cells transfected with either control siRNA (siLuc) or siRNA targeting Rab7A were infected with
VSV-G pseudotyped NL4-3 HIV-1 (WT or Udel) at a MOI of 0.5. Twenty-four hours later the cells were stained with mouse monoclonal antibody against
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concomitant reduction of BST2 expression at the cell surface,
probably due to a block in the recycling of BST2 from endosomes.
We also explored the effect of Rab7A silencing on Vpu-
mediated downregulation of cell surface BST2. siRNA transfected
HeLa cells were infected with VSV-G pseudotyped WT or Udel
NL4-3 HIV-1 at a MOI of 0.5 so that approximately 50% of the
cells were infected. Cell surface levels of BST2 were assessed by
flow cytometry (Figures 8C and 8D). Cell surface staining of Env
(SUgp120) was used to distinguish non-infected cells (Figures 8C
and 8D, gate C1 and black bars) from infected cells (Figures 8C
and 8D, gate C2 and grey bars). In control cells (siRNA Luc)
infected with HIV-1 WT, BST2 cell surface expression decreased
by $35% compared with non-infected cells, consistent with
previous studies [28,29,54,56,62]. Depletion of Rab7A reduced
cell surface BST2 levels on non-infected cells ($35%) or on Udel
infected cells ($38%), compared to the corresponding control cells
(siLuc). Moreover, cell surface expression of BST2 was not
downregulated further upon HIV-1 infection in Rab7A knock-
down cells (Figure 8C, compare gate C2 to C1 on the upper 2nd
panel).
A fraction of BST2 persists at the cell surface upon Rab7A
depletion
BST2/Tetherin impedes the release of HIV-1 by physically
tethering fully formed mature particles to the plasma membrane of
infected cells. Vpu abrogates this function by reducing the cell
surface expression of BST2, thus allowing efficient virus release
[28,29,52,54,55]. Our data show that Rab7A depletion impairs
the release of HIV (Figures 2 and 3), an effect that seems to be
related to the expression of BST2 (Figure 5). However,
surprisingly, the cell surface expression of BST2 was reduced in
the Rab7A knockdown cells (Figure 8).
To understand how Rab7A depletion can lead to reduced HIV-
1 release and to the accumulation of viruses at the cell surface
(Figure 4), despite reducing cell surface BST2 levels, we analyzed
more closely the location of cell surface BST2 in infected siRNA
treated cells by immunofluorescence staining (Figure 9). HeLa cells
were treated with siRNA against Rab7A (siRab7A) or control
siRNA (siLuc), then infected with VSV-G pseudotyped wt and
Udel viruses and processed for labelling of cell surface Env and
BST2. Infected cells, identified by staining for Env, are indicated
on Figure 9A with white stars. Control cells (siLuc) infected with wt
HIV-1 showed reduced BST2 staining at the cell surface
compared to neighbouring non-infected cells (Figure 9A, HIV-1
WT, panels b and c). As expected, the cell surface expression of
BST2 was not changed in control cells (siLuc) infected with Udel
HIV-1 (Figure 9A, HIV-1 Udel, panels h and i). These results are
consistent with Vpu-induced BST2 cell surface downregulation
[29,54,56,62]. Similar to the results shown in Figure 8, silencing of
Rab7A induced an overall decrease of BST2 cell surface
expression in both non-infected and infected cells (Figure 9A,
compare panels b and h to e and k, respectively). Quantification of
the colocalization between BST2 and Env at the cell surface using
Pearson’s correlation coefficient [61] revealed the presence of
BST2 in Env positive areas in Rab7A-depleted cells to a similar
extent as in control cells infected with Udel viruses (Figure 9B),
whereas almost no colocalization was observed between BST2 and
Env in control cells infected with wt viruses. Similar results were
obtained after quantification of MAp17/BST2 colocalization at
the cell surface (Figure S6). These data suggest that, upon
depletion of Rab7A, a fraction of BST2 remains in Env and MA
positive patches at the cell surface, even in the presence of Vpu.
Discussion
The small GTPase Rab7A plays a major role in regulating
trafficking through the late endocytic pathway. Indeed, Rab7A
controls the transport of cargoes through late endosomes,
facilitates endosome maturation and regulates the interaction of
endosomes with the cytoskeleton [35–46]. Here we show that
Rab7A expression is required for the efficient propagation of
infectious HIV-1. Several components of the cellular trafficking
machineries have previously been shown to be involved in the late
steps of the HIV-1 replication cycle. These include the ESCRT
machinery, as HIV-1 Gag recruits TSG101, an ESCRT-I
component, or ALIX, an ESCRT-associated protein, to mediate
the final scission events that release virus particles from the plasma
membrane [24–27]. Moreover, HRS, a component of the
ESCRT-0 complex, is involved in Vpu-induced BST2 cell surface
downregulation and degradation, thereby contributing to efficient
HIV-1 release [30]. The clathrin adaptor complexes AP-1 and AP-
3, as well as TIP47, ARF and GGA proteins, also contribute to
Gag and Env trafficking through the cell and are required for
efficient production of infectious HIV-1 [9–20]. The involvement
of Rab7A in the release of infectious HIV-1 further highlights the
importance of the vesicular trafficking machinery in the life cycle
of HIV-1.
A number of Rab proteins have previously been implicated in
HIV-1 replication. Rab5A, which coordinates endocytosis and
early endosome function, has been reported to regulate the early
events of HIV-1 infection in polarized human trophoblasts [63].
Silencing of Rab5A did not significantly alter HIV-1 propagation
in our assay (Figure 1), possibly because HIV entry in HeLa P4-R5
cells may occur mainly by fusion of the virus with the cell surface, a
Rab5A-independent process. A functional genomic screen using
siRNAs identified the Golgi-localized Rab6A, which controls
retrograde transport from the Golgi apparatus to the endoplasmic
reticulum (ER), as a cellular factor required for HIV-1 dissemi-
nation [49] and efficient HIV entry. The late steps of HIV-1
replication, including trafficking of Gag and Env and the assembly
and release of new viral particles, also depend on the expression of
key Rab proteins. Efficient HIV-1 replication and Gag trafficking
requires expression of Rab9A [48], a Rab protein regulating
sorting of cargoes along the late endocytic pathway from late
endosomes to the TGN. Our data corroborate these findings,
showing that Rab9A expression is important for efficient spreading
of HIV-1, and also illustrate that Rab proteins regulating exocytic
membrane traffic support efficient HIV propagation in cell culture
(Figure 1). We observed that Rab4A, Rab8A and Rab11A, key
regulators of the recycling pathway, are required for HIV
dissemination in our assay, in part confirming previous reports
BST2 (BST2; upper panels) or control mouse IgG1 as an isotype control (CT IgG; lower panels), along with human anti-Env antibody (2G12). The cells
were then stained with Alexa 647-conjugated donkey anti-mouse and PE-conjugated donkey anti-human antibodies, fixed and processed for flow
cytometry analysis. (C) Dot plot. Vertical lines indicate the gates set using non-infected cells stained as indicated. Gate C1 represents non-infected
cells and gate C2 infected cells. These data are representative of 3 independent experiments. (D) Bar graph representation of the cell surface levels of
BST2 (Mean of fluorescence Intensity; MFI) on Env negative cells (black bars) and Env positive cells (grey bars) for each siRNA condition. Bars represent
the means of the MFI values 6 SD from 3 independent experiments.
doi:10.1371/journal.ppat.1002347.g008
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steps that are regulated by Rab4A and Rab8A are not defined,
and further studies will be necessary to characterize the role of
these two Rab proteins in HIV-1 replication.
The present study highlights an unsuspected and major role for
Rab7A, a key player of the late endocytic pathway, in the HIV
replication cycle. Rab7A depletion strongly decreased HIV-1
dissemination in HeLa P4-R5 cells (Figure 1). We observed a
significant, though mild effect of Rab7A knockdown on HIV-1
entry. However, this only accounts for a minor part of the dramatic
alteration of HIV propagation observed in these cells (Figure S2).
Indeed, our virus release assays documented that Rab7A knock-
down considerably reduced HIV-1 infectivity and release (Figures 2
and 3). Analysis of viruses produced by Rab7A knockdown cells
suggested that Rab7A is required for efficient processing of the Env
glycoprotein; virus particles produced in Rab7A-depleted cells
incorporated mainly the immature Env precursor, gp160, and were
poorly infectious (Figures 3B and 3C). Moreover, our analysis of
Env processing revealed a defect in Env maturation in the absence
of Rab7A expression (Figures 3D and 3E). Env maturation to the
TMgp41 and SUgp120 subunits by cellular endoproteases is
essential for HIV-1 infectivity [64,65]. Rab7A may regulate the
trafficking of Env and/or furin or furin-like proteases that are
responsible for Env processing. In the absence of Rab7A, trafficking
of Env through furin-containing compartments may be reduced,
leading to an accumulation of Env precursors in the producer cells
and on viruses. Rab7A knockdown could also induce mislocaliza-
tion of Env and/or furin, reducing their encounter in the cell and
thus Env processing. The Env maturation defect could also be the
consequence of the increased levels of Env in Rab7A knockdown
cells. Alteration of the late endocytic pathway upon Rab7A
depletion could lead to an accumulation of Env in endocytic
compartments or the TGN to levels that exceed the processing
capacity of the cellular endoproteases, thereby interfering with the
maturation of newly synthesized Env.
In addition to the effect on Env processing and HIV-1
infectivity, Rab7A silencing impaired HIV-1 release from infected
cells (Figure 2). Fewer virus particles were released into the
medium upon Rab7A depletion, and instead viruses accumulated
in large clusters at the cell surface, as demonstrated by immu-
nofluorescence and immuno-electron microscopy experiments
(Figure 4). In addition, we observed an increase in the levels of
cell-associatedEnvand Gagproteins.AsRab7Aisakeyregulatorof
the late endocytic pathway, which has been previously described to
be involved in the degradation of excess viral proteins in in-
fected cells [50,51], alterations in endo/lysosomal degradation in
Figure 9. Env SUgp120 and BST2 proteins colocalize at the cell surface of Rab7A-depleted cells. HeLa cells transfected with either siRNA
control Luciferase (siLuc) or siRNA targeting Rab7A (siRab7A) were infected with either VSV-G pseudotyped wt NL4-3 HIV-1 (HIV-1 WT) viruses or VSV-
G pseudotyped Vpu-defective NL4-3 (HIV-1 Udel) viruses. (A) Twenty-four hours after infection, cells were stained at 4uC with anti-Env and anti-BST2
antibodies and appropriate fluorophore-conjugated secondary antibodies. Cells were then fixed with PFA, permeabilized and labelled with DAPI.
Infected cells are indicated with white stars. Scale bars=20 mm. (B) Env-BST2 colocalization was assessed by calculating the Pearson correlation
coefficient on twenty images per condition using the JACoP plugin on ImageJ.
doi:10.1371/journal.ppat.1002347.g009
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viral proteins. In addition, the accumulation of clusters of viruses at
the surface of infected Rab7A knockdown cells (Figure 4 and S4)
may also contribute to the increased levels of viral products
associated with the cells. The accumulation of virus clusters at the
cell surface has been previously observed following infection of
BST2-expressing cells with Vpu-defective HIV-1, suggesting that
the effect of Rab7A knockdown on HIV release could be related to
BST2 expression [28,29,57]. This hypothesis is supported by the
fact that HIV release was less affected when Rab7A was silenced in
cells devoid of BST2 (e.g. in non-restrictive 293T cells, Figures 5A
and 5B) or in BST2-depleted HeLa cells (Figures 5C and 5D).
BST2/Tetherin has been identified as a cellular restriction
factor that impedes the release of HIV-1 by physically tethering
fully formed mature virus particles to the plasma membrane of
infected cells [28,29,55]. The HIV-1 protein Vpu acts as a
countermeasure to BST2, downregulating BST2 from the cell
surface and enhancing its degradation, thereby rescuing efficient
virus release [28,29,54,55]. BST2 has been shown to internalize via
clathrin-coated pits and recycle from endosomes, probably via the
trans-Golgi network (TGN) and/or recycling endosomes [62,66],
while a proportion of the protein is degraded in lysosomes [30]. In
HIV infected cells, Vpu counteracts the restriction imposed by
BST2 by inhibiting this cycling and enhancing the lysosomal
degradation of BST2 [30,54,56,67], thereby decreasing the levels
of cellular and cell surface BST2 [28,29,52]. We show here that
Rab7A, which regulates exit from late endosomes/MVB, is
required for sorting of BST2 to lysosomes and degradation.
Depletion of Rab7A by RNA interference prevents lysosomal
degradation of the protein, thereby increasing cellular BST2 levels
(Figure 6), both in the presence and absence of Vpu (Figure 7).
Rab7A knockdown may also block exit from MVB to other routes.
As a result, we observed a large build-up of BST2 in late
endosomes and MVB/CD63+ compartments (Figures 6B and
6D). Recycling of BST-2 to the cell surface might also be reduced,
leading to lower BST2 expression at the cell surface (Figure 8). In
addition reduced access of newly synthesized BST2 to the cell
surface could also contribute to the decreased cell surface
expression of BST2 observed upon Rab7A depletion. Alternatively
Rab7A knock-down may induce an alteration of the expression
level or localization of a cellular cofactor regulating BST2
trafficking. Nonetheless, some newly synthesized BST2, together
with some leak-through recycling of BST2 from MVB, could still
reach the cell surface (Figure 9), leading to the tethering of virus to
the plasma membrane (Figure 4).
Exactly how Rab7A supports the sorting of BST2 to lysosomes
and its degradation is not clear. BST2 was recently shown to be
ubiquitinated and Vpu expression was shown to increase this
ubiquitination [68,69]. Furthermore, b-TRCP2, a subunit of the
Skp1-cullin1-F-Box (SCF) ubiquitin ligase complex is required for
Vpu to downregulate BST2 expression [53,54,56,62] and the SCF
ubiquitin ligase complex was shown to be recruited to endocytic
membranes [70]. We might speculate that Rab7A knockdown
alters b-TRCP2 recruitment, perturbing Vpu-induced ubiquitina-
tion of BST2, and thus blocking its downregulation. We cannot
exclude that other E3 ligases or unidentified cellular cofactors of
BST2 or Vpu that are important for Vpu-induced downregulation
of BST2 could be mislocalized, downregulated or upregulated
upon Rab7A knockdown. It has recently been shown that RING-
type E3 ubiquitin ligase, BCA2/Rabring7 (Breast cancer-associ-
ated gene 2), a cellular cofactor of BST2 contributes to the
restriction of HIV-1 particle production by accelerating the
internalization and degradation of viral particles [71]. BCA2
directly binds Rab7A and thereby plays a crucial role in vesicle
trafficking to late endosomes and lysosomes [72,73]. Silencing of
Rab7A may alter this function of BCA2. However, overexpression
of BCA2 in BST2 restrictive cells did not lead to the same
phenotype as that observed on HIV production in Rab7A-
depleted cells, suggesting that the role of Rab7A on HIV release is
not related to BCA2. However, these differences could be
explained by the fact that overexpression of this Rab7 effector
does not impair the late endocytic pathway, but instead activate it
[71]. Further experiments will be necessary to decipher the
molecular mechanisms by which Rab7A blocks Vpu-induced
downregulation of BST2. Indeed, Rab7A could also regulate
another tethering factor that may contribute to retaining viruses.
This idea is supported by the observation that, after double
knockdown of both Rab7A and BST2 (Figures 5C and 5D), HIV
release was still impeded, though not as much as in BST2-
expressing cells.
Rab7A has been previously shown to be involved in the entry of
several viruses such as Semliki Forest virus, Parvoviruses, Dengue
and West Nile virus, by sorting them to late endosomes after their
internalization [74–77]. Here, we show that Rab7A regulates the
production of infectious HIV-1 particles. Rab7A is required for
efficient Env processing, allowing the proper incorporation of
mature Env glycoproteins. Rab7A also promotes HIV release by
controlling the trafficking and degradation of BST2, and by
contributing to the mechanism by which Vpu counteracts this
restriction factor. These studies highlight new roles of a major
component of the late endocytic pathway, Rab7A, in the late steps
of the HIV replication cycle. Although the precise molecular and
cellular mechanisms by which Rab7A mediates these effects
remain to be elucidated, our data bring significant new insights to
understanding HIV assembly, restriction by BST2/Tetherin and
how Vpu uses cellular machineries, and particularly the endocytic
pathway, to counteract this host cell restriction factor, thereby
favoring HIV-1 dissemination.
Materials and Methods
Cell culture
HeLa, HeLa P4-R5 MAGI (NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID), HeLa
TZM-bl (NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID) and HEK 293T cells were grown in
DMEM plus glutamine, antibiotics and 10% decomplemented-
FCS (fetal calf serum) (GibcoBRL, Invitrogen, France). HeLa P4-
R5 MAGI cell cultures were supplemented with 100 mg/mL
geneticin and 1 mg/mL puromycin.
siRNA transfection and reagents
Small interfering RNA (siRNA) transfections were performed
with 5 to 30 nM siRNA using Lipofectamine RNAiMAX
(Invitrogen), according to the reverse transfection procedure
described in the manufacturer’s instructions.
ON-TARGETplus SMARTpool Rab1A (L-008283-00-0005),
Rab4A (L-008539-00-0005), Rab5A (L-004009-00-0005), Rab6A
(L-008975-00-0005), Rab8A (L-003905-00-0005) and Rab11A (L-
004726-00-0005), synthesized by Thermo Scientific Dharmacon
(Perbio Science, France), target Rab1A, Rab4A, Rab5A, Rab6A,
Rab8A, and Rab11A mRNAs, respectively (see also Figure S1).
Rab7A siRNA (5’GGGAGAUUCUGGAGUCGGGAAdTdT3’)
and Rab7A-2 siRNA (5’CCACAAUAGGAGCUGACUUdTdT3’)
target the Rab7A mRNA at positions 274–294 and 348–366
respectively. Rab9A siRNA (5’CGGCAGGUGUCUACAGAA-
GdTdT3’) targets the Rab9A mRNA at positions 573–591. The
On-TARGETplus SMART pool siRNA targeting BST2 was
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luciferase (5’CGUACGCGGAAUACUUCGAdTdT3’) which tar-
gets the P. Pyralis firefly GL2 luciferase mRNA sequence (positions
515–535) was used as control (Thermo Scientific Dharmacon).
Viral stocks
Stocks of wild type NL4-3 HIV-1 (NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID) or NL4-
3/Udel HIV-1 (from Dr. K. Strebel [78]) were obtained by
transfection of HEK 293T cells (2610
6) with 6 mg of the
corresponding proviral DNA, using the Fugene reagent as
recommended by the manufacturer (Roche Diagnostics, France).
VSV-G pseudotyped virus was generated by transfection of HEK
293T cells (2610
6) with 1.5 mg of VSV-G expression vector
(pMD.G) along with 4.5 mg of HIV-1 proviral DNA (pNL4–3,
pNL4-3/Udel). Supernatants of the transfected cells were collected
after 48 h, filtered and quantified for the HIV-1 CAp24 antigen by
ELISA (Innotests HIV Antigen mAb, Innogenetics, France). Viral
titres were assessed by infection of the indicator cells HeLa TZM-
bl (bearing the b-galactosidase gene under the control of HIV-1
LTR) with serial dilutions of the stocks, followed by a b-
galactosidase coloration of the cells and counting of blue cells.
Recombinant DNA and transfection procedures
Rab7A WT cDNA was cloned into pEGFP-C vector (Clontech,
France). The inactive form of Rab7A (Rab7A T22N) was made by
PCR mutagenesis using the QuikChange II site directed
mutagenesis kit (Stratagene, France). All mutagenesis and
subclonings were verified by DNA sequencing. Transient
transfections of HeLa cells (5610
5) with mammalian expres-
sion vectors (3 mg) were performed using Lipofectamine LTX
with PLUS Reagent (Invitrogen), following the manufacturer’s
instructions.
HIV-1 propagation assay
HeLa P4-R5 MAGI cells (1610
5) transfected with siRNA were
infected with NL4-3 HIV-1 at a MOI of 0.005. Six hours after
infection, cells were washed and placed in fresh medium.
Supernatants were collected every 24 h for 4 days. HIV-1
propagation was monitored by the X-gal staining of infected cells
and by the ELISA quantification of CAp24 antigen released into
the cell culture supernatants after multiple rounds of infection. For
X-gal staining, cells were fixed with 0.5% glutaraldehyde solution
and stained with X-Gal solution (4 mM potassium ferrocyanide
hydrate, 4 mM potassium ferricyanide, 2 nM MgCl2, and
0.4 mg/ml X-Gal, 5-bromo-4-chloro-3-indolyl b-D-galactopyra-
noside).
In parallel, infected cell cultures were lysed and extracts were
analyzed for Rab protein expression by western blotting using
rabbit anti-Rab1A (Abcam, UK), goat anti-Rab4A (Santa Cruz
Biotechnology, France), rabbit anti-Rab5A (Santa Cruz Biotech-
nology), rabbit anti-Rab6A (Santa Cruz Biotechnology), mouse
anti-Rab7A (Sigma), goat anti-Rab8A (Santa Cruz Biotechnolo-
gy), mouse anti-Rab9A (ABR, France), rabbit anti-Rab11A (Santa
Cruz Biotechnology), and mouse anti-tubulin (DM1A, Sigma)
antibodies.
HIV-1 entry assay
For the entry assays, CD4
+ CCR5
+ CXCR4
+ HeLa P4-R5
MAGI cells (5610
5) transfected with siRNA were infected with
wild-type NL4-3 HIV-1 or wild-type NL4-3 HIV-1 pseudotyped
with VSV-G at a MOI of 0.005. Cells were washed 4 h later and
placed in fresh medium supplemented with AMD3100 (Sigma), a
CXCR4 inhibitor. After 24 h, cells were fixed with 0.5%
glutaraldehyde solution and stained with X-Gal solution as
described above.
HIV-1 production and infectivity assays
For HIV-1 production assays in a single round of infection,
HeLa cells (2610
5) were treated with siRNA as described above.
HEK 293T cells (3610
5) were treated with 20 nM siRNA. After
48 h, the cells were infected with NL4-3 (WT or Udel) HIV-1
pseudotyped with VSV-G for 6 h at a MOI of 0.5. Twenty-four
hours after infection, supernatants were collected, 0.45 mm-filtered
and used for HIV-1 CAp24 quantification by ELISA (released
CAp24). Viral particles released into the supernatant were pel-
leted through a 20% sucrose cushion by ultracentrifugation at
150,000 g for 90 min and resuspended in Laemmli sample buffer.
Pelleted viruses were analyzed by western blotting using rabbit
anti-CAp24 (4250; NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID). The cell lysates were
analyzed by western blotting using rabbit anti-CAp24, rabbit anti-
Vpu (NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID), mouse anti-Rab7A, rabbit anti-BST2
(NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID) and mouse anti-Tubulin (Sigma) antibodies.
In a single round infection assay, the titres of released viruses
were determined by infection of the indicator cells HeLa TZM-bl.
24 hours later, cells were fixed with 0.5% glutaraldehyde and
stained with X-Gal solution (see above). HIV-1 infectivity
corresponded to the ratio of the titre of the produced virus to
the quantity of CAp24 detected in the supernatant.
Incorporation assays and quantification of HIV-1 viral
genomic RNA
Forty-eight hours after siRNA transfection, HeLa cells were
infected with VSV-G pseudotyped wt NL4-3 HIV-1 (NL4-3 WT)
treated with DNase I (Roche Diagnostics, 0.1 units/ml) plus MgCl2
(10 mM) at 37uC for 1 h to eliminate residual proviral DNA used
to prepare viral stocks. Supernatants of infected cells were
harvested 24 h later, 0.45 mm-filtered, and virions pelleted
through a 20% sucrose cushion by ultracentrifugation at
150 000 g for 90 min, and resuspended in PBS. Producer cells
were collected and pelleted. Half of the producer cells and pelleted
virus preparations were lysed in lysis buffer (50 mM Tris pH 7.5,
150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-100, 0.1% (v/v)
sodium deoxycholate) and quantified by CAp24 ELISA, or
analyzed by western blotting using rabbit anti-CAp24, mouse
anti-SUgp120 (110H, Hybridolab, France) and human anti-
TMgp41 (41A, Hybridolab), rabbit anti-MAp17 (VU47; NIH
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID), mouse anti-Rab7A, and mouse anti-Tubulin
antibodies.
The remaining half of the producer cell and virus preparations
was used for quantification of viral genomic RNA. Prior to RNA
purification, non-infected HeLa cells (1610
6) were added to each
virus sample to control for the efficiency of RNA extraction and
reverse transcription assays of the viral preparation for quantitative
real-time PCR as described below. RNA from the virus samples or
producer cells was purified (RNeasy Mini Kit, Qiagen, France)
and treated with DNase I (0.5 U/ml) for 20 min at 30uC. DNase I
was then heat-inactivated for 10 min at 75uC. 1 mg of total RNA
was used for reverse transcription by using random hexamers with
M-MLV reverse transcriptase (Moloney Murine Leukemia Virus
RT; Invitrogen) to generate cDNA for real-time PCR analysis. To
remove RNA complementary to the cDNA, samples were treated
for 20 min at 37uC with RNAse H (0.05 U/ml; Invitrogen) and
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an equivalent amount of RNA was used to perform the identical
reaction in the absence of M-MLV RT. Real-time PCR was
performed by using LightCycler FastStart DNA MasterPlus SYBR
Green I reaction mix on a LightCycler instrument with Light-
Cycler software (Version 3.5; Roche Applied Science). Real-time
PCR conditions consisted of four consecutive segments as follows:
a preincubation segment of 1 cycle of 10 min at 95uC; an
amplification segment consisting of 40-45 cycles of 2 s at 95uC, 5 s
at 55uC, and 5 s at 72uC; and finally a melting-curve segment and
a cooling segment, which were performed as described by the kit’s
manufacturer. Unspliced genomic HIV-1 RNA (gRNA) was
selectively amplified by using primers La8.1 (5’-CTGAAGCGCG-
CACGGCAA-3’) and L9 (5’-GACGCTCTCGCACCCATCTC-
3’) [79]. This pair forms a 100 bp-amplified fragment correspond-
ing to HIV-1 NL4-3 gag sequences from positions 705 to 805. To
determine the relative quantity of unspliced viral transcripts for
each sample, cDNA corresponding to human GAPDH was
amplified (GAPDH1: 5’-GGGTCATCATCTCTGCACCT-3’ -
GAPDH2: 5’-GGTCATAAGTCCCTCCACGA-3’) and used as
an internal control for normalization.
SDS-PAGE and western blot analysis
Cells were lysed for 30 min at 4uC using lysis buffer (50 mM
Tris pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-
100, 0.1% (v/v) sodium deoxycholate), supplemented with
complete protease inhibitor cocktail (Roche Diagnostics). Cell
lysates were spun for 10 min at 20,000 g and supernatants were
recovered and mixed with 2x Laemmli sample buffer, (Sigma).
Samples were boiled and proteins resolved on 12% SDS–PAGE
gels. Proteins were transferred onto Hydrophobic polyvinylidene
difluoride (PVDF) membranes and incubated in blocking solution
(TBS–0.05% (v/v) Tween 20 supplemented with 5% (w/v) milk)
for 30 min. Blots were rinsed with TBS containing 0.05% (v/v)
Tween 20 and incubated with primary antibody in the blocking
solution overnight. The membranes were rinsed as before and
incubated for 30 min with the appropriate HRP-conjugated
secondary antibody diluted in the blocking solution. The mem-
branes were rinsed again and immunodetections were performed
using the enhanced chemiluminescence ECL substrate (GE
healthcare Europe GMB, France).
For Env quantification, the membranes were incubated with
anti-SUgp120 (110H) and TMgp41 (41A), washed and incubated
with Dylight-800 Goat Anti-mouse IgG antibody (KPL, Gaithers-
burg, USA). The corresponding signals were then acquired with
the Odyssey Infrared Imaging System (Li-Cor) for further
quantification using ImageJ software.
Immunofluorescence microscopy
For intracellular staining of CA and Env, cells were grown on
cover slips, fixed with 4% (w/v) paraformaldehyde (PFA) in PBS
for 20 min, permeabilized and blocked with 0.2% (w/v) BSA/
0.1% (w/v) saponin in PBS (blocking solution) for 30 min. Cells
were then incubated for 30 min with mouse anti-CAp24 (25A,
Hybridolab) and human anti-Env HIV-1 gp120 (2G12, National
Institute for Biological Standards and Control Centralised Facility
for AIDS Reagents, NIBSC) in blocking solution. Cells were
washed and incubated for 30 min with Alexa 488-conjugated
donkey anti-mouse and Alexa 594-conjugated goat anti-human
antibodies (Invitrogen).
For extracellular staining of Env, living cells were incubated for
1 h at 4uC with human anti-Env HIV-1 gp120 antibody (2G12).
Cells were then labelled with Alexa 594-conjugated goat anti-
human antibody, washed, fixed with 4% PFA in PBS for 20 min,
permeabilized and blocked for 30 min in blocking solution. Cells
were then incubated for 30 min with mouse anti-MAp17 (18A,
Hybridolab) in blocking solution as described above, washed and
labelled for 30 min with Alexa 488-conjugated donkey anti-mouse
antibody.
For intracellular staining of BST2, cells grown on cover slips
were permeabilized in PBS/0.1% BSA/0.05% saponin before
fixation with 4% PFA in PBS for 15 min [80]. PFA-fixed cells were
permeabilized and blocked for 30 min, and incubated for 30 min
with mouse polyclonal anti-BST2 (Abnova, Germany) alone
or along with anti-Env HIV-1 gp120 antibody (2G12). Cells
were then washed and incubated for 30 min with appropriate
fluorophore-conjugated secondary antibodies.
For colabelling of BST2 with CD63, HeLa cells transfected with
either siRNA control Luciferase (siLuc) or siRNA targeting Rab7A
were labelled with mouse polyclonal anti-BST2 antibody followed
by an Alexa 594-conjugated donkey anti-mouse antibody. Cells
were then incubated in blocking solution containing mouse serum
(10%) for 20 min before immunolabelled with mouse anti-LAMP-
3(CD63)-FITC (MX-49.129.5, Santa Cruz).
For extracellular staining of BST2, living cells were incubated
for 1 h at 4uC with mouse monoclonal anti-BST2 (Abnova) alone
or together with human anti-Env HIV-1 gp120 (2G12). Then,
cells were labelled with appropriate fluorophore-conjugated
secondary antibodies, washed, fixed with 4% PFA in PBS for
20 min, permeabilized and blocked for 30 min. For MAp17/
BST2 colabelling, living cells were incubated for 1 h at 4uC with
rabbit polyclonal anti-BST2 (NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID), then labelled with
appropriate fluorophore-conjugated secondary antibodies,
washed, fixed with 4% PFA in PBS for 20 min, permeabilized
and blocked for 30 min. Cells were then incubated for 30 min
with mouse anti-MAp17 (18A, Hybridolab) in blocking solution as
described above.
Stained cells were analyzed with a Leica DMI 6000 microscope
or Leica Spinning Disk confocal microscope. Series of optical
sections were recorded and image processing was performed using
ImageJ and Adobe Photoshop CS2 software. Quantitative Env/
BST2 and CD63/BST2 colocalization analysis was done with
JACoP tool (ImageJ software) using Pearson’s correlation coeffi-
cient [61]. The estimation of Pearson’s correlation coefficient is
one of the standard techniques applied for matching one image to
another in order to describe the degree of overlap between two
channels, taking into account the environment of each pixel. A
value of +1 is the result of complete co-localization between two
channels. The Pearson coefficient was calculated for twenty
images per condition, with about 10 cells per image. Bars
represent the mean 6 SD from each image.
Immunolabelling of cryosections for electron microscopy
Cells transfected with siRNAs and infected with VSV-G
pseudotyped wt NL4-3 HIV-1 were fixed in 4% PFA in 0.1 M
sodium phosphate buffer, pH 7.4, embedded in gelatine, and
frozen for cryosectioning, as described previously [81,82]. For
immuno-EM, ultrathin cryosections (50 nm) were quenched in
50 mM glycine-50 mM NH4Cl in PBS and stained with the
human anti-Env mAb 2G12 and 10 nm PAG (Protein A gold
reagents were obtained from the EM Lab, Utrecht University,
Utrecht, The Netherlands). Sections were fixed in 1% (v/v)
glutaraldehyde for 10 min, re-quenched in 50 mM glycine-
50 mM NH4Cl in PBS and incubated with mouse antibodies
against CAp24 (38:96K and EF7, ARP365 and 366, respectively,
from B. Wahren, National Bacteriological Laboratory, Stockholm,
Sweden) or p17 (4C9, ARP342 obtained from R.B. Ferns and R.S.
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obtained through the National Institute for Biological Standards
and Control Centralised Facility for AIDS Reagents (South
Mimms, Hertfordshire, UK), followed a rabbit anti-mouse bridging
antibody (DakoCytomation, Ely, UK), and 5 nm PAG. Alterna-
tively, sections were stained with mouse polyclonal antibodies
against BST2 or double stained with rabbit anti-BST2 and mouse
anti-CD63 (antibody 1B5, see [81]). Sections were embedded in
uranyl acetate in methylcellulose, as described [82], and examined
with a Technai G2 Spirit transmission electron microscope (FEI
Company UK. Ltd., Cambridge, UK). Digital images were
recorded with a Morada 11 MegaPixel TEM camera (Olympus
Soft Imaging Solutions) and the AnalySIS software package. Images
were adjusted for brightness and contrast, and figures were
assembled with Photoshop CS.
Flow cytometry analysis
Forty-eight hours after siRNA transfection, non-infected cells
were harvested by scraping, washed twice in cold PBS/1% (w/v)
BSA and stained for 1 h at 4uC with mouse monoclonal anti-
BST2 antibody (Abcam) or control mouse IgG1 (BD Biosciences)
in PBS/1% BSA. The cells were then washed three times in PBS/
1% BSA, and stained for 1 h at 4uC with an Alexa 647-conjugated
donkey anti-mouse antibody in PBS/1% BSA. Cells were washed
and fixed in 4% PFA before analysis using the Cytomics FC500
Flow Cytometer (Beckman Coulter).
Alternatively, cells were transfected with siRNAs and, after
48 h, infected with NL4-3 (WT or Udel) HIV-1 pseudotyped with
VSV-G at a MOI of 0.5. Twenty-four hours after infection, cells
were harvested by scraping, washed twice in cold PBS/1% BSA
and stained for 1 h at 4uC with mouse monoclonal anti-BST2
antibody (Abcam) or control mouse IgG1 (BD Biosciences),
together with the human anti-Env antibody (2G12) in PBS/1%
BSA. The cells were washed three times in PBS/1% BSA, and
stained for 1 h at 4uC with Alexa 647-conjugated donkey anti-
mouse and PE-conjugated donkey anti-human antibodies in PBS/
1% BSA. Cells were washed and fixed in 4% PFA before analysis
using the Cytomics FC500 Flow Cytometer. Data acquisition was
performed at the Cochin Immunobiology Facility. Gates for PE
were set using non-infected cells.
Analysis of BST2 turnover
Forty-eight hours after siRNA transfection, cells were pre-
incubated for 45 min with DMEM with 10 mM Hepes, 1 mg/ml
BSA (Calbiochem, VWR, France) and 10 mg/ml cycloheximide
(Calbiochem). The cells were then washed and incubated for the
indicated times in regular growth medium supplemented with
10 mM Hepes, 10 mg/ml cycloheximide, and 150 ng/ml Epider-
mal Growth Factor (EGF) (Invitrogen, France), where indicated.
The cells were harvested, washed in PBS, lysed and analyzed by
western-blotting as described before.
Supporting Information
Figure S1 Analysis of Rab proteins depletion. (A)
Schematic representation of the Rab sequences targeted by
commercial pool siRNAs and designed siRNAs (Rab7A, Rab7A-
2 and Rab9A). Black bars correspond to the Rab ORF, and blue,
green, red and yellow bars correspond to the positions of the
siRNA-targeted sequences. Rab1A siRNA pool from Dharmacon
(5’CAGCAUGAAUCCCGAAUAU; 5’GUAGAACAGUCUUU-
CAUGA; 5’GGAAACCAGUGCUAAGAAU; 5’UGAGAA-
GUCCAAUGUUAAA) targeted Rab1A mRNA, respectively at
positions 392–410, 867–885, 839–857, 941–959. Rab4A siRNA
pool from Dharmacon (5’GAAAGAAUGGGCUCAGGUA;
5’GUUAACAGAUGCCCGAAUG; 5’UUAGAAGCCUCCA-
GAUUUG; 5’UACAAUGCGCUUACUAAUU) targeted Rab4A
mRNA respectively at positions 764–782, 529–547, 623–641 and
509–527. Rab5A siRNA pool from Dharmacon (5’GCAAGCAA-
GUCCUAACAUU; 5’GGAAGAGGAGUAGACCUUA; 5’AG-
GAAUCAGUGUUGUAGUA; 5’GAAGAGGAGUAGACCUU-
AC) targeted Rab5A mRNA respectively at positions 736–754,
962–979, 999–1019 and 963–980. Rab6A siRNA pool from
Dharmacon (5’GAGAAGAUAUGAUUGACAU; 5’GAGCAAC-
CAGUCAGUGAAG; 5’AAGCAGAGAAGAUAUGAUU; 5’CC-
AAAGAGCUGAAUGUUAU) targeted Rab6A mRNA respec-
tively at positions 1075–1093, 1113–1131, 1070–1088 and 955–
973. Rab7A siRNA (5’GGGAGUUCUGGAGUCGGGAA) and
Rab7A-2 siRNA (5’CCACAAUAGGAGCUGACUU3’) targeted
Rab7A mRNA, respectively, at positions 274–294 and 348–366.
Rab8A siRNA pool from Dharmacon (5’GAAUUAAACUGCA-
GAUAUG; 5’GAACAAGUGUGAUGUGAAU; 5’GAACUG-
GAUUCGCAACAUU; 5’GAAGACCUGUGUCCUGUUC) tar-
geted Rab8A mRNA respectively at positions 389–407, 582–600,
522–540 and 282–300. Rab9A siRNA (5’CGGCAGGTGTCTA-
CAGAAG) targeted Rab9A mRNA at positions 573–591. Rab11A
siRNA pool from Dharmacon (5’GGAGUAGAGUUUGCAA-
CAA; 5’GUAGGUGCCUUAUUGGUUU; 5’GCAACAAU-
GUGGUUCCUAU; 5’CAAGAGCGAUAUCGAGCUA) target-
ed Rab11A mRNA respectively at positions 261–279, 381–399,
703–721 and 336–354. (B) HeLa P4-R5 MAGI cells were
transfected with siRNAs against luciferase (siLuc) or the different
Rab proteins (siRab). Cells lysates were separated by SDS/PAGE
and subjected to western blotting with rabbit anti-Rab1A, goat anti-
Rab4A, rabbit anti-Rab5A, rabbit anti-Rab6A, mouse anti-Rab7A,
goat anti-Rab8A, mouse anti-Rab9A, rabbit anti-Rab11A, or
mouse anti-tubulin (as a loading control) antibodies.
(TIF)
Figure S2 Impact of Rab7A depletion on HIV-1 entry.
HeLa P4-R5 MAGI cells transfected with either control siRNA
Luciferase (siLuc) or siRNAs targeting Rab7A protein (siRab7A)
were infected with NL4-3 HIV-1 (HIV-1) (A) or with NL4-3 HIV-
1 pseudotyped with VSV-G (VSV-G HIV-1) (B) at a low
MOI=0.005. HIV-1 entry corresponds to the number of infected
blue cells counted in siRNA-treated HeLa P4-R5 MAGI cells after
one round of infection. This experiment is representative of 6
experiments performed in duplicate. Bars represent the mean of
the number of infected cells 6 SD from duplicates in one
experiment.
(TIF)
Figure S3 Impact of Rab7A depletion on virus release
and genomic RNA encapsidation into particles. (A-C)
HeLa cells transfected with either siRNA control Luciferase (siLuc)
or siRNA targeting Rab7A proteins (siRab7A and siRab7A-2)
were infected with the VSV-G-pseudotyped HIV-1. Viruses and
producer cells were collected. This experiment is representative of
3 independent experiments done in duplicate. HIV-1 CAp24
released into the supernatant of the infected cells (Released
CAp24, grey graphs bars) (A) and present within the cells (Cell-
associated CAp24, black graph bars) (B) were measured by ELISA
quantification. (C) HIV-1 Infectivity corresponds to the ratio of
the titre of produced virus to the quantity of released CAp24
(Infectious units/mg CAp24). HIV-1 infectivity values obtained for
Rab-depleted cells were normalized to those obtained for the
control cells, set as 100%. Bars represent the mean 6 SD from
duplicates of one experiment. RNA was extracted from the cell (E)
or virus samples (D) and subjected to reverse transcription
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(gRNA) were selectively amplified using La8.1 and La9 primers.
Values obtained for viral genomic RNA were determined relative
to those obtained for GAPDH amplification and then normalized
to those obtained for the control cells, set as 100%. As a negative
control, an equivalent amount of RNA was used to perform the
identical reaction in the absence of M-MLV RT (RT control). (F)
Viral RNA extracted from each viral sample was normalized to
the amount of CAp24 released and is shown relative to the RNA
from the control cells, set as 100%. Bars represent the means of the
percentages 6 SD from duplicates of one experiment.
(TIF)
Figure S4 Most of the HIV particles at the surface of
Rab7A knockdown cells have a mature morphology.
HeLa cells transfected with siRNA targeting Rab7A (siRab7A)
were infected with VSV-G-pseudotyped HIV-1 for 24 h and then
fixed and processed for EM immunolabelling. (A) Ultrathin
cryosections were double labelled for Env with 10 nm protein A-
gold particles and CAp24 and 5 nm protein A-gold. The
immunogold labelling allows identification of virus particles and
distinguishes viruses from microvilli (MV) that have a similar
diameter. CAp24 labelling is also seen on particles with immature
morphology (arrows). These particles have a slightly larger
diameter and smooth circular outline, with a thick layer of
oligomerized Gag underneath the viral membrane. (B, C, D)
Ultrathin cryosections were double labelled for Env with 10 nm
protein A-gold particles and MAp17 and 5 nm protein A-gold. (B)
Viruses budding from the surface of a cell. As the antibody 4C9
only binds the cleaved mature MAp17, immature virus particles
and buds (arrows) remain generally unlabelled. By contrast,
mature HIV particles are strongly stained for MAp17 (marked V).
(C, D) Most of the clustered virus particles at the cell surface are
strongly labelled for MAp17, indicating that they are mature,
tethered virions. Scale bars=200 nm.
(TIF)
Figure S5 Effect of over-expression of the inactive form
of Rab7A, T22N, on BST2 turnover and distribution.
HeLa cells were transfected with either wild type Rab7A (GFP-
Rab7A WT) or the inactive form of Rab7A (GFP-Rab7A T22N).
(A) Forty-eight hours after transfection, cells were incubated with
cycloheximide (10 mg/ml) for 0 or 4 hours. Cells were lysed and
equivalent amounts of each sample (50 mg of protein) were
analyzed using western blotting with antibodies against BST2,
GFP and tubulin as a loading control. This experiment is
representative of 3 independent experiments. (B) Forty-eight
hours after transfection, cells were permeabilized before fixation
and stained with mouse polyclonal anti-BST2 and Alexa 594-
conjugated donkey anti-mouse antibodies. Scale bars =20 mm.
(TIF)
Figure S6 Effect of Rab7A silencing on MAp17 and BST2
co-distribution. HeLa cells transfected with either siRNA
control Luciferase (siLuc) or siRNA targeting Rab7A (siRab7A)
were infected with VSV-G pseudotyped wt NL4-3 HIV-1 (HIV-1
WT) viruses. (A) Twenty-four hours after infection, cells were
stained at 4uC with rabbit polyclonal BST2 antibodies and
appropriate fluorophore-conjugated secondary antibodies. Cells
were then fixed with PFA, permeabilized, labelled with mouse
monoclonal MAp17 antibodies and DAPI. Infected cells are
indicated with white stars. Scale bars =20 mm. (B) MA-BST2
colocalization was assessed by calculating the Pearson correlation
coefficient on twenty images per condition using the JACoP plugin
on ImageJ.
(TIF)
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